Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory Submissions
The PMDA enters 8th consecutive year of using Certara’s biosimulation software
June 23, 2021 19:00 ET | Source: Certara Certara Princeton, New Jersey, UNITED STATES
PRINCETON, N.J., June 23, 2021 (GLOBE NEWSWIRE) Certara, a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ and Phoenix™ biosimulation software. The PMDA has been using Certara’s biosimulation software since 2014.
The Simcyp Physiologically-Based Pharmacokinetic (PBPK) Simulator is used in drug development to determine first-in-human dose, design more efficient and effective clinical studies, and predict drug-drug interactions using virtual populations. The Phoenix Pharmacokinetic and Pharmac
Operator
Good day, and thank you for standing by. Welcome to the Certara first-quarter 2021 earnings conference call. [Operator instructions] Please be advised that today s conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, David Deuchler, investor relations.
Please go ahead.
Investor Relations
Good afternoon, everyone. Thank you all for participating in today s conference call. On the call from Certara, we have William Feehery, chief executive officer; and Andrew Schemick, chief financial officer. Earlier today, Certara released financial results for the quarter ended March 31, 2021.
A copy of the press release is available on the company s website. Before we begin, I d like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securitie
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Certara fourth-quarter 2020 earnings conference call. [Operator instructions] Please be advised that today s conference may be recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, David Deuchler, investor relations. Please go ahead, sir.
David Deuchler
Investor Relations
Good afternoon, everyone. Thank you for participating in today s conference call. On the call from Certara, we have William Feehery, chief executive officer; and Andrew Schemick, chief financial officer. Earlier today, Certara released financial results for the quarter and year ended December 31st, 2020.